SPC
RCKT icon

Sigma Planning Corp’s Rocket Pharmaceuticals RCKT Stock Holding History

Sigma Planning Corp’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,575
Closed -$157K – 1325
2025
Q1 		$157K Buy
23,575
+200
+0.9% +$1.98K 0.01% 1137
2024
Q4 		$294K Sell
23,375
-1,500
-6% -$22.6K 0.01% 936
2024
Q3 		$459K Sell
24,875
-30
-0.1% -$614 0.01% 772
2024
Q2 		$536K Sell
24,905
-575
-2% -$13.2K 0.02% 694
2024
Q1 		$686K Buy
25,480
+13,610
+115% +$387K 0.02% 639
2023
Q4 		$356K Sell
11,870
-13,910
-54% -$307K 0.03% 578
2023
Q3 		$528K Sell
25,780
-307
-1% -$5.58K 0.02% 690
2023
Q2 		$518K Sell
26,087
-1,508
-5% -$30.5K 0.02% 721
2023
Q1 		$473K Buy
27,595
+1,275
+5% +$25K 0.02% 819
2022
Q4 		$515K Hold
26,320
– – 0.02% 752
2022
Q3 		$420K Buy
26,320
+5,030
+24% +$78.5K 0.02% 803
2022
Q2 		$293K Buy
21,290
+7,230
+51% +$86.2K 0.01% 1002
2022
Q1 		$223K Buy
+14,060
New +$243K 0.01% 1194

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Sigma Planning Corp's RCKT Position: Q2 2025 in Review

Sigma Planning Corp sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 23,575 shares — an estimated $157K sold.

Sigma Planning Corp first reported a position in RCKT in Q1 2022 and held it in 13 quarters. The position peaked at $686K in Q1 2024. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Sigma Planning Corp reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Sigma Planning Corp sold 23,575 Rocket Pharmaceuticals shares in Q2 2025, an estimated $157K.
  • Sigma Planning Corp first reported a position in Rocket Pharmaceuticals in Q1 2022 and held it in 13 quarters.
  • Sigma Planning Corp's Rocket Pharmaceuticals position peaked at $686K in Q1 2024.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Sigma Planning Corp's 13F filing for Q2 2025, filed 5 Aug 2025.